Sabra Health Care REIT, Inc. (SBRA) Stock Price & Analysis
Sabra Health Care REIT, Inc. (SBRA) closed at USD 19.6 on Thursday, October 22, 2026, up 3.70% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 18.9; the Oct 22, 2026 session ranged USD 18.88–19.66 on volume of 2,428,532 shares. Market capitalization is $5.01B, with a 52-week range of USD 17.17–22.77 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SBRA.md
Key facts (SBRA)
- Last four reported quarters (through Jun 30, 2026): revenue $860M, net income $65.4M (7.6% margin) (SEC filings).
- Valuation: P/E 76.5x (avg 101.2x at the last 3 fiscal year-ends), net debt $2.39B.
- Analysts: Hold (mean 2.56 on a 1–5 scale) (16 analysts), mean target USD 22.36 (range 19–25).
- Total return with dividends: 1Y +14.3% vs S&P 500 +14.9%; 5Y +93.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 0.17, revenue estimate $236M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SBRA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $570M | $625M | $648M | $703M | $775M | $860M |
| Net income | -$113M | -$77.6M | $13.8M | $127M | $156M | $65.4M |
| EPS (diluted) | -$0.52 | -$0.34 | $0.06 | $0.54 | $0.64 | — |
| Net margin | -19.9% | -12.4% | 2.1% | 18.0% | 20.1% | 7.6% |
| Revenue growth | -4.8% | +9.7% | +3.6% | +8.6% | +10.2% | — |
| Cash + short-term investments | $112M | $49.3M | $41.3M | $60.5M | $71.5M | — |
| Total debt | $2.39B | $2.51B | $2.41B | $2.42B | $2.53B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SBRA)
P/E 76.5x · P/S 5.8x · EV/Sales 8.6x · P/B 1.8x · Earnings yield 1.31% · Dividend yield (paid, TTM) 5.95% · Net debt $2.39B · EV $7.40B
P/E at fiscal year-ends: Dec 2025 29.8x, Dec 2024 32.3x, Dec 2023 241.5x.
Analysts (SBRA)
Consensus Hold (mean 2.56 on a 1–5 scale), 16 analysts; mean target USD 22.36 (low 19, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Wells Fargo | Target lowered | Overweight | $23 → $21 |
| 2026-10-13 | UBS | Target lowered | Neutral | $21 → $20 |
| 2026-10-13 | Barclays | Target lowered | Equal-Weight | $23 → $21 |
| 2026-08-31 | Barclays | Target raised | Equal-Weight | $21 → $23 |
| 2026-08-31 | Baird | Target raised | Neutral | $20 → $21 |
| 2026-08-06 | Raymond James | Upgrade | Underperform → Market Perform | |
| 2026-07-22 | Baird | Target raised | Neutral | $22 → $23 |
| 2026-07-22 | Truist Securities | Target raised | Buy | $22 → $24 |
| 2026-07-22 | Citizens | Target raised | Market Outperform | $23 → $25 |
| 2026-07-08 | UBS | Target lowered | Neutral | $22 → $21 |
| 2026-07-08 | Truist Securities | Upgrade | Hold → Buy | $22 |
| 2026-07-07 | Barclays | Initiated | Equal-Weight | $21 |
Total return (dividends reinvested) (SBRA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +14.3% | +93.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +14.4% | +14.1% |
| Volatility (annualized) | 24.6% | 24.8% |
| Max drawdown | -16.1% (May 2026→Jun 2026) | -32.5% (Aug 2022→Mar 2023) |
SBRA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.17 | $0.17 | -2.9% | $236.4M | 2 |
| Next quarter (ends Dec 2026) | $0.18 | $0.17 | +1.9% | $243.3M | 3 |
| Current fiscal year (ends Dec 2026) | $0.40 | $0.69 | -41.2% | $926.5M | 8 |
| Next fiscal year (ends Dec 2027) | $0.81 | $0.74 | +9.0% | $1.02B | 2 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 19.6 |
|---|---|
| Change | ▲ 3.70% (up) |
| Previous Close | USD 18.9 |
| Open | USD 18.97 |
| Day Range | USD 18.88 – 19.66 |
| 52-Week Range | USD 17.17 – 22.77 |
| Volume | 2,428,532 shares |
| Market Cap | $5.01B |
| Exchange | NMS |
Technical Analysis (SBRA)
Nexqual's technical model rates SBRA "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.12 (neutral) |
| vs SMA50 | Below (USD 19.97) |
| MACD | -0.2 (negative) |
Analyst Ratings (SBRA)
Wall Street analysts rate SBRA "Hold" based on 16 analysts, with a mean price target of USD 22.36 (range USD 19–25), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 22.36 |
| High Target | USD 25 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 6 / 10 / 0 |
Earnings (SBRA)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD 0.17 |
| Revenue Estimate | $236.37M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.15 vs est 0.17 ▼ miss |
| 2026-03-31 | USD 0.16 vs est 0.16 ▲ beat |
| 2025-12-31 | USD 0.16 vs est 0.16 ▼ miss |
| 2025-09-30 | USD 0.17 vs est 0.18 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (SBRA)
| Total Revenue | $863.77M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +25.30% |
| Gross Margin | +50.27% |
| Operating Margin | -12.53% |
| Profit Margin | +7.58% |
| ROE | +2.39% |
| Debt / Equity | 0.96 |
| Current Ratio | 3.57 |
| Total Cash | $246.31M |
| Total Debt | $2.63B |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (SBRA)
Nexqual rates Sabra Health Care REIT, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 50%, operating -13% (last 12 months) |
| Balance Sheet | Mixed — $232M cash and investments vs $2.63B debt (Jun 2026, SEC) |
| Cash Flow | Solid — Operating cash flow $349M (FY ended Dec 2025, 10-K) |
| Efficiency | Weak — ROE 2%, ROA 1.9% |
Ownership (SBRA)
| Insider Ownership | +1.41% |
|---|---|
| Institutional Ownership | +105.28% |
| Shares Outstanding | 255.46M |
| Float | 251.33M |
| Short % of Float | +10.69% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (SBRA)
Sabra Health Care REIT, Inc. is led by Richard K. Matros, Chairman, President & CEO, per Nexqual as of October 23, 2026 at 10:11 UTC.
| Chairman, President & CEO | Richard K. Matros |
|---|---|
| Executive VP, CFO & Treasurer | Michael Lourenco Costa |
| Executive Vice President of Strategic Initiatives | Peter W. Nyland |
| Executive Vice President of Finance | Lukas Michael Hartwich C.F.A. |
Major Backers & Investors (SBRA)
Notable institutional backers of Sabra Health Care REIT, Inc. include Principal Financial Group, Inc., Principal Funds, Inc-Real Estate Securities Fund, CenterSquare Investment Management LLC, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Principal Financial Group, Inc. | 9.67% |
| Principal Funds, Inc-Real Estate Securities Fund | 3.24% |
| CenterSquare Investment Management LLC | 2.28% |
| Bank of America Corporation | 2.07% |
| Charles Schwab Investment Management, Inc. | 1.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.29% |
| Vanguard Group | 13.58% |
| State Street | 4.82% |
| Geode Capital | 3.1% |
| Nuveen | 1.75% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HR | Healthcare Realty Trust Incorpo | USD 17.93 | ▲ 4% |
| NHI | National Health Investors, Inc. | USD 66.96 | ▲ 3.14% |
| CTRE | CareTrust REIT, Inc. | USD 36.62 | ▲ 2.72% |
| LTC | LTC Properties, Inc. | USD 43.33 | ▲ 2.7% |
| AHR | American Healthcare REIT, Inc. | USD 53.4 | ▲ 1.02% |
| DHC | Diversified Healthcare Trust | USD 7.87 | ▲ 2.34% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt